012 AACU STATE SOCIETY NETWORK ADVOCACY CONFERENCE

Press Releases on September 23rd, 2012 No Comments

The American Association of Clinical Urologists held its 5th Annual State Society Network Advocacy Conference in late September 2012. During the conference, New Jersey Assemblyman Herb Conaway, Jr., MD accepted the organization’s Distinguished Leadership Award, having been nominated by urologists in New Jersey for his work promoting the interests of patients and physicians in the legislature. Of these urologists, New Jersey Patient Care and Access Coalition President David Taylor, MD sponsored this nomination. Dr. Taylor highlighted Dr. Conaway’s commitment to public service as well as leadership on issues very important to the urologic community.

Dr. Conaway has served in the New Jersey General Assembly since 1998, as the only member with both a medical and law degree. He specializes in internal medicines and practices in Willingboro where he supports and focusses on prostate-specific antigen-based screening for prostate cancer and access to patient-centered integrated care.

Dr. Taylor and Dr. Conaway at the State Advocacy Conference

NJPCAC COMMEMORATES PROSTATE CANCER AWARENESS MONTH WITH “STATE HOUSE WEEK”

Press Releases on June 21st, 2012 No Comments

The New Jersey Patient Care and Access Coalition commemorated “Prostate Cancer Awareness Month” in New Jersey with a special educational display in the State House in Trenton the week of June 18th through 21st.

Participating in the event were:

Dr. David Taylor, President and Chairman of NJPCAC
NJPCAC Board Member Alan Plotkin
NJPCAC Board Member Dr. Eric Seaman
NJPCAC Board Member Mary Beth Guilbert
Dr. Bill Niedrach from Delaware Valley Urology
Kelly Snyder from The Stone Center
NJPCAC Lobbyist Donald Sico

The group was able to have conversations with scores of legislators and staffers during the week and help educate them regarding prostate cancer treatment and symptoms as well as the dangerous United States Preventative Services Task Force recommendations on PSA screening. In addition, the Great Prostate Cancer Challenge race in September was promoted.

NEW JERSEY LEADS THE NATION IN OPPOSING USPSTF PSA TESTING RECOMMENDATION

Press Releases on January 17th, 2012 No Comments

New Jersey became the first state in the nation to formally oppose the draft recommendation made by the U.S. Preventive Services Task Force (USPSTF) that healthy men should no longer receive prostate-specific antigen (PSA) blood tests as part of routine cancer screening. The joint resolution requesting the U.S. Congress to seek the withdrawal of the USPSTF’s dangerous recommendation, which was passed unanimously by the Senate and the Assembly and signed into law by the Governor, was a quick, bold and courageous move that clearly put our State on the side of early detection of cancer and, ultimately, aving lives. New Jersey men, especially men with a family history of prostate cancer, as well as the underinsured, men living in rural areas and African Americans, can applaud our legislature and Governor for this triumph.

Now, a new study published on March 15 in the New England Journal of Medicine has proven once again how valuable PSA screening is as a life-saving tool and just how right our leaders were in acting so quickly to seek the withdrawal of the USPSTF recommendation. A follow-up of the European Randomized Study of Screening for Prostate Cancer (ERSPC) confirmed what practicing urologists have known for decades: PSA screening saves lives.
In the study, “Prostate-Cancer Mortality at 11 Years of Follow-up,” PSA screening was shown to reduce the mortality rate of prostate cancer by 29 percent. The ERSPC, the world’s largest prostate cancer screening study, involved 182,160 men between the ages of 50 and 74 years at entry, with a predefined core age group of 162,388 men 55 to 69 years of age. The trial was conducted in eight European countries. Men who were randomly assigned to the screening group were offered PSA-based screening, whereas those in the control group were not offered screening. The results showed that for all patients, there was a 21% survival advantage, and more importantly, for those with follow-up of more than 10 years, the survival advantage increased to 38%.

New Jersey public policy makers, including Governor Chris Christie, Senators Loretta Weinberg and Joseph Vitale and then-Assembly members Joan Quigley and Alex DeCroce quickly understood the dangers inherent in the USPSTF recommendation against PSA screening. Senator Weinberg remembered that the USPSTF was the very same task force that, in 2009, recommended against mammograms for women ages 40-49 and against teaching women to do breast self-exams. Our legislators understood the seriousness of the USPSTF’s latest recommendation and in a show of bi-partisan support unanimously passed the resolution in both houses – sending a clear message to men in New Jersey who, upon hearing news reports of the USPSTF recommendation, might decide to forego routine PSA screening.

It is important for patients to know that PSA screening is not treatment. It is a simple blood test. There are essentially no risks to screening, and with screening results, patients have the information they need to consult with their families and their doctors to make better informed decisions about their health.

African American men are especially in need of this information as well as those with a family history of prostate cancer. The facts are not in dispute: One in six men will be diagnosed with prostate cancer in his lifetime and this figure increases to one in five for African-American men; and African-American have more than twice the prostate cancer mortality rate of white men.

As Chairman of the New Jersey Patient Care and Access Coalition (NJPCAC), a coalition of nearly 200 practicing urologists and scores of additional healthcare professionals, including radiation oncologists, pathologists, and nurse oncologists from across the state, I understand what is at stake here. We are united in our opposition to this new recommendation and we have good reason. According to the American Cancer Society, approximately 7,840 New Jersey men will be diagnosed with prostate cancer this year. Roughly 1,100 of them will eventually die from the disease. And while that is an unacceptable number and we can do better, it is significantly better than a few short years ago because of PSA screenings.

Few would disagree that the decision on how and when to screen and treat prostate cancer should stay where it has always been: between patients and their doctors. As a physician, I have been trained not to be an alarmist nor to be prone to exaggeration, but I believe that the USPSTF draft recommendation, if finalized, will cause the needless deaths of thousands of men. As the State of New Jersey has unanimously stated, the USPSTF recommendation must be rejected.

Dr. David Taylor is President and Chairman
of the New Jersey Patient Care and Access Coalition. He is also President of
Garden State Urology and practices in Morristown, NJ.

NJPCAC HOSTS LEGISLATOR OPEN HOUSE IN HONOR OF PROSTATE CANCER AWARENESS MONTH

Press Releases on October 1st, 2010 No Comments

The New Jersey Patient Care and Access Coalition (NJPCAC), a coalition of more than 200 top urologists and other healthcare professionals, hosted an open house event on September 30 from 1-4 pm in Room 109 (State House) in honor of September being recognized as Prostate Cancer Awareness Month.
NJPCAC is a physician driven advocacy group focused on addressing the challenges facing our healthcare system and ensuring that patients continue to receive the highest quality, accessible medical care in the state of New Jersey.

NJPCAC’s membership includes over 160 practicing urologists, as well as pathologists and radiation oncologists, along with scores of additional healthcare professionals and administrative staff, that have come together to educate policy makers, regulators, insurers and other key stakeholders, including patients and peers about regulatory changes that will adversely affect the quality and accessibility to care provided to patients in New Jersey and those that will advance care in New Jersey. NJPCAC physicians treat patients in five of the largest multi-specialty group practices that focus on urologic care in the State as well as The Stone Center of New Jersey in Newark (which is one of the largest lithotripsy centers in the United States).

NJPCAC and its member practices and physicians view themselves as trusted partners on whom legislators and other government decision-makers can rely.

NJPCAC ANNOUNCES PARTNERSHIP WITH ZERO – THE PROJECT TO END PROSTATE CANCER TO HOST 2011 GREAT PROSTATE CANCER CHALLENGE EVENT IN NEW JERSEY

Press Releases on August 20th, 2010 No Comments

The New Jersey Patient Care and Access Coalition, comprised of more than 160 urologists from across the State, announced today a partnership with ZERO – The Project to End Prostate Cancer to host a Great Prostate Cancer Challenge 5k Race in 2011 that will raise money to promote prostate cancer awareness, early detection and research.

NJPCAC’s member physicians are joining colleagues in 11 states across the country and in the District of Columbia to partner with ZERO in what has become the premier prostate cancer event series in America.

“NJPCAC could not be more delighted to be partnering with ZERO – The Project to End Prostate Cancer to bring the Great Prostate Cancer Challenge race series to the State of New Jersey,” said Dr. Adam Perzin, the Chairman of NJPCAC’s Board of Directors. Dr. Perzin noted that “NJPCAC physicians, including urologists, pathologists and radiation oncologists, are on the front lines in furnishing care for men with prostate cancer, and our Coalition coming together to team with ZERO to put together the first GPCC race in New Jersey is extremely exciting.”

The GPCC races bring together athletes, cancer survivors, physicians, caretakers, family members and friends. ZERO – The Project to End Prostate Cancer, along with large urology group practices, has grown the national race series to include races in 11 states across the country with an estimated 7,000 participants. Since the national race series began in 2008, more than $1 million has been raised to promote prostate cancer awareness, early detection and research.

Dr. Perzin said that details for the 2011 GPCC event in New Jersey will be announced in the coming months and that the event is likely to be held in Camden, New Jersey, with potential expansion to other parts of the State in future years.

NJPCAC TAPPED TO ASSIST LEGISLATIVE LEADERSHIP IN DRAFTING NEW JERSEY’S LAWS ON OUT OF NETWORK PROVIDERS

Press Releases on April 8th, 2010 No Comments

The New Jersey Patient Care and Access Coalition (NJPCAC), comprised of more than 160 urologists from across the State, has been asked by Gary Schaer, Chair of the Assembly Financial Institutions and Insurance Committee, to participate in a small panel of stakeholders to craft legislation directed at addressing the challenges surrounding those health care professionals and facilities that opt out of insurance company networks. Physicians from NJPCAC have been representing the Coalition (and every individual physician in New Jersey) and attending private, small workgroup meetings with Schaer and other legislative and Administration officials. Chairman Schaer expects to have the out of network legislation completed by the early fall and plans that the Legislature will take action on the final bill before the holidays.

COALITION FORMED TO PRESERVE ACCESS TO HIGHEST QUALITY UROLOGIC CARE FOR NEW JERSEY PATIENTS

Press Releases on September 25th, 2008 No Comments

A statewide collection of multi-specialty physician group practices have formed a coalition aimed at promoting and protecting the highest quality urologic care for New Jersey patients. The New Jersey Patient Care and Access Coalition (NJPCAC) will seek to educate and partner with policy makers, regulators, insurers and other key stakeholders, including patients and other physician organizations, to ensure that New Jersey citizens continue to have access to the highest quality urologic care, including an integrated and comprehensive approach to the diagnosis and treatment of prostate cancer.

“Urology patients in New Jersey and the physicians and other healthcare professionals who care for them have a new and robust voice that will work to protect and expand access to the highest quality urologic care in our State,” said the Chairman of NJPCAC’s Board of Directors, Dr. Adam Perzin. “NJPCAC’s goal is simple – be a trusted voice on behalf of patients, physicians and other healthcare professionals committed to safeguarding the finest urologic care for citizens of our great State.”

Dr. Perzin noted that, through NJPCAC, multi-disciplinary physician group practices furnishing the full range of urologic services have lent their voices in communicating with State policy makers and regulators about the importance of preserving an integrated, comprehensive model of cancer care treatment for men battling prostate cancer — the second leading cause of cancer death in American men. The physician practices supporting this effort range in size from 12 to 40 physicians and are located across the entire State of New Jersey.